Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: Alternatives for analysis of an irreversible positron emission tomography tracer for measurement of acetylcholinesterase activity in human brain

Journal of Cerebral Blood Flow and Metabolism

Volumn 19, Issue 10, 1999, Pages 1150-1163

  Koeppe, Robert A ^a   Frey, Kirk A ^a   Snyder, Scott E ^a   Meyer, Phillipp ^a   Kilbourn, Michael R ^a   Kuhl, David E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Acetylcholinesterase; N 11C methylpiperidin 4 yl propionate; Positron emission tomography; Tracer kinetics

Indexed keywords

CARBON 11; PROPIONIC ACID DERIVATIVE; TRACER;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN EXPERIMENT; HYDROLYSIS; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0033497793     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004647-199910000-00012     Document Type: Article

References (26)

1. Asthana S, Greig NH, Hegedus L, Holloway HH, Raffaele KC, Schapiro MD, et al (1995) Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 58:299-309
2. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH (1986) Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 47:263-277
3. Bevington PR (1969) Data Reduction and Error Analysis for the Physical Sciences, New York, McGraw-Hill, pp 232-241
4. Frey KA, Koeppe RA, Kilbourn MR, Snyder SE, Kuhl DE (1997a) PET quantification of cortical acetylcholinesterase inhibition in monkey and human. J Nucl Med 38:146P
5. Frey KA, Koeppe RA, Kilbourn MR, Snyder SE, Schwarz R, Callahan MJ, et al (1997a) PET quantification of acetylcholinesterase activity in monkey brain without blood sampling: methodology and effect of THA. J Cereb Blood Flow Metab 17:S328
6. Frey KA, Holthoff VA, Koeppe RA, Jewett DM, Kilbourn MR, Kuhl DE (1991) Parametric in vivo imaging of benzodiazepine receptor distribution in human brain. Ann Neurol 30:663-672
7. 11C]scopolamine and positron emission tomography. J Cereb Blood Flow Metab 12:147-154
8. Hucho F, Jarv J, Wiese C (1991) Substrate-binding sites in acetylcholinesterase. Trends Pharmacol Sci 12:422-426
9. Irie T, Fukushi K, Akimoto Y, Tamagami H, Nozaki T (1994) Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol 21,801-808
10. Irie T, Fukushi K, Namba H, Iyo M, Tamagami H, Nagatsuka S, et al (1996) Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. J Nucl Med 37,649-655
11. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, et al (1997) Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349:1805-1809
12. Koeppe RA (1990) Compartmental modeling alternatives for kinetic analysis of PET neurotransmitter/receptor studies. In: Frontiers in Nuclear Medicine: In Vivo Imaging of Neurotransmitter Functions in Brain, Heart, and Tumors (Kuhl DE, ed), Washington D.C., American College of Nuclear Physicians, pp 113-139
13. Koeppe RA (1996) Tracer kinetics: principles of compartmental analysis and physiologic modeling. In: Nuclear Medicine, vol 1 (Henkin RE, ed), St Louis, Mosby Year Book, pp 292-315
14. 11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab 16:1288-1299
15. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735-744
16. Koeppe RA, Frey KA, Snyder SE, Kilbourn MR, Kuhl DE (1997a) Evaluation of two distinct kinetic analyses for use with [C-11]PMP: an irreversible tracer for mapping AChE activity. J Cereb Blood Flow Metab 17:5329
17. Koeppe RA, Frey KA, Snyder SE, Kilboum MR, Kuhl DE (1997b) Kinetic analysis alternatives for assessing AChE activity with N-[C-11]methylpiperidin-4-yl propionate (PMP): to constrain or not to constrain? J Nucl Med 38:198P
18. Kilbourn MR, Nguyen TB, Snyder SE, Koeppe RA (1998) One for all of one for each? Matching radiotracers and brain pharmacokinetics. In: Quantitative Functional Brain Imaging with Positron Emission Tomography (Carson RE, Daube-Witherspoon ME, Herscovitsch P, eds), San Diego, Academic Press, pp 261-265
19. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, et al (1999) In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 52:691-699
20. Kühl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR (1996) Mapping acetylcholinesterase in human brain using PET and N-[C-11]methylpiperidin-4-yl propionate (PMP). J Nucl Med 37(5):21P
21. Namba H, Iyo M, Shinotoh H, Nagatsuka S, Fukushi K, Irie T (1998) Preserved acetylcholinesterase activity in aged cerebral cortex. Lancet 351:881-882
22. Pappata S, Tavitian B, Traykov L, Jobert A, Dalger A, Mangin JF, et al (1996) In vivo imaging of human cerebral acetylcholinesterase. J Neurochem 67:876-879
23. Reinikainen KJ, Reikkinen PJ, Paljarvi L (1988) Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data. Neurochem Res 13:135-146
24. 11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol 25:751-754
25. Somani SM, Khalique A (1987) Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. Drug Metab Dispos 15(5):627-633
26. Tavitian B, Pappata S, Planas AM, Jobert A, Bonnot-Lours S, Crouzel C, et al (1993) In vivo visualization of acetylcholinesterase with positron emission tomography. Neuroreport 4:535-538